DoD Breast Cancer Breakthrough Award Levels 1 and 2

Post Date

March 28th 2014

Application Due Date

May 28th 2014

Funding Opportunity Number

W81XWH-14-BCRP-BREAKTHROUGH12

CFDA Number(s)

12.420

Funding Instrument Type(s)

Cooperative Agreement
Grant

Funding Activity Categories

Science and Technology and other Research and Development

Number of Awards

30

Eligibility Categories

Unrestricted

Funding

• Estimated Total Funding:

  $39000000

• Award Range:

  $None - $None

Grant Description

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome. Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement/Funding Opportunity. Funding Levels 3 and 4 are available under a different Program Announcement (W81XWH-14-BCRP-BREAKTHROUGH34). It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the research proposed. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level: ╔ Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development. Research with potential to yield new avenues of investigation. Proof of concept. No preliminary data required. ╔ Funding Level 2: Research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation. Demonstration of efficacy in in vivo models, as applicable. Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive collaborations between investigators. The Partnering PI Option is structured to accommodate two PIs, called the Initiating PI and the Partnering PI, each of whom will receive a separate award. The Initiating and Partnering PIs have different submission requirements; however, both PIs should contribute significantly to the development of the proposed research project including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. New collaborations are encouraged, but not required. It is the responsibility of the PIs to describe how their combined expertise will better address the research question and explain why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly addressing distinct research questions. Personnel: The PI(s) are expected to engage and assemble an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project. Consumer Advocates: Applications submitted under Funding Levels 1 and 2 are encouraged, but not required, to include consumer advocate involvement. Consumer advocates may be involved in the development of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer, and they should be active in a breast cancer advocacy organization. Their role in the project should be independent of their employment, and they cannot be employees of any of the organizations participating in the application. The consumer advocates should have a high level of knowledge of current breast cancer issues, and the necessary background or training in breast cancer research to contribute to the project.

Contact Information

• Agency

  Department of Defense

• Office:

  Dept. of the Army -- USAMRAA

• Agency Contact:

  CDMRP Help Desk
  Phone: 301-682-5507
  Email: help@eBRAP.org
  

• Agency Mailing Address:

  CDMRP Help Desk

• Agency Email Address:

  help@eBRAP.org